

Special Issue

Emerging Issue of Inflammatory Bowel Diseases

Message from the Guest Editor

Inflammatory bowel diseases (IBDs) are currently crucial pathologies. We still do not know their exact origin, and despite the ongoing era of biologics in their treatment, Crohn's disease and ulcerative colitis tend to be somehow unpredictable in their course. We gather continuously more information related to IBDs. To emphasize the current role of IBDs and to explore molecular pathways involved in their development, we highly encourage you to publish in the Special Issue of Biomedicines titled Emerging Issue of Inflammatory Bowel Diseases. The scope of the manuscripts should be related to the following topics: Original data on novel markers in the diagnosis IBDs and in the prediction of their flare up;

Possible new indicators of the positive treatment response;

New approaches in the management of IBDs, including combinations of biologics;

Markers predicting the natural history of IBDs;

Comorbidities observed in patients with IBDs and the general outcome in this population;

The context of colorectal cancer in patients with IBDs;

Future perspectives for IBDs, including medical and social aspects.

Guest Editor

Dr. Agata Michalak

Department of Gastroenterology with Endoscopy Unit, Medical University of Lublin, 20-954 Lublin, Poland

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/212948

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).